Investors Who Acquired Wise Group Securities Encouraged to Contact Kehoe Law Firm

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Wise Group plc (“Wise,” “Wise Group,” or the “Company”) (NASDAQ: WSE).

A securities class action lawsuit has been filed against Wise and certain of its executives on behalf of investors who purchased or otherwise acquired publicly traded Wise securities between May 11, 2026 and July 23, 2026, both dates inclusive (the “Class Period”).

The action, captioned Daugherty v. Wise Group plc, et al., Case No. 1:26-cv-06582, was filed on July 31, 2026, in the United States District Court for the Southern District of New York.

Allegations Against Wise Group

The class action complaint alleges that the Wise Group defendants made materially false and/or misleading statements and failed to disclose material adverse facts concerning Wise’s business, operations, and prospects. Specifically, the complaint alleges that the defendants failed to disclose that Wise’s regulatory risks were materially understated as a result of allegedly deficient anti-money laundering efforts and insufficient efforts to prevent the financing of terrorism.

The complaint further alleges that, as a result, the defendants’ statements concerning Wise Group’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

Belgian Money-Laundering Investigation

According to the complaint, Reuters reported on June 1, 2026, that the Brussels Public Prosecutor’s Office was investigating Wise’s European entity in connection with matters reportedly involving more than half a billion euros, or approximately $582.5 million, in suspicious transactions.

The complaint states that Reuters reported that the investigation concerned potential money-laundering offenses with alleged connections to fraud, corruption, and drug trafficking. Prosecutors were also reportedly investigating whether international criminal organizations had used Wise Europe’s services.

According to the complaint, following this news, Wise’s U.S.-listed shares declined $0.67 per share, or 5.24%, to close at $12.10 per share on June 1, 2026. The shares subsequently declined $0.56 per share, or 4.6%, to close at $11.54 per share on June 2, 2026, and declined an additional $0.82 per share, or 7.1%, to close at $10.72 per share on June 3, 2026.

OCC Denies Wise’s National Trust Bank Application

On July 24, 2026, The Wall Street Journal reported that the Office of the Comptroller of the Currency had denied Wise’s application to establish a national trust bank.

The OCC stated that the application presented significant supervisory and compliance concerns. Among other matters, the OCC identified deficiencies relating to Wise’s anti-money laundering and countering the financing of terrorism program.

According to the complaint, following this news, Wise’s U.S.-listed shares declined $0.75 per share, or 6.2%, to close at $11.33 per share on July 24, 2026.

September 29, 2026 Lead Plaintiff Deadline

Investors who purchased or otherwise acquired publicly traded Wise securities during the Class Period may, no later than September 29, 2026, seek appointment as lead plaintiff.

Investors are not required to seek appointment as lead plaintiff to remain potential members of the class. The lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Wise Investors May Have Legal Claims

Investors who acquired Wise Group securities during the Class Period and suffered financial losses are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to discuss the class action, the lead plaintiff process or their legal rights.  

There is no cost or obligation to speak with the firm.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR).

FDA Concerns About the Effectiveness Data for Capricor’s Cell Therapy for Heart Condition Related to Duchenne Muscular Dystrophy

On July 27, 2026, the U.S. Food and Drug Administration (“FDA”) released briefing materials concerning Capricor’s application for FDA approval of deramiocel, an investigational cell therapy for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy.

According to Reuters, “FDA staff reviewers raised concerns about the effectiveness data for Capricor Therapeutics’ cell therapy for a heart condition related to Duchenne muscular dystrophy . . ..” Reuters reported that “[t]he agency’s staff said Capricor changed ⁠how it measured the main results after the therapy’s late-stage trial ended, calculating arm-function performance ​as a percentage change instead of the original plan of analyzing scores in a 42-point ​test.”

On July 29, 2026, Stocktwits (via Yahoo Finance) reported that “[s]hares of Capricor . . . are on track for a record weekly selloff after an [FDA] advisory panel voted 9-3 against Deramiocel . . ..”

Stocktwits further reported that “[t]he FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee concluded on Wednesday that Capricor had not shown substantial evidence that Deramiocel effectively treats cardiomyopathy in DMD. Several panelists said the data was not convincing enough.”

On this news, shares of Capricor stock declined approximately 67%, closing at $6.57 per share on July 29, 2026. In premarket trading on July 30, 2026, Capricor shares fell an additional 50%, trading below $3.00 per share.

Capricor Securities Class Action Filed 

On July 30, 2026, a class action alleging violations of federal securities laws was filed on behalf of Capricor investors who purchased or otherwise acquired Capricor securities between December 17, 2025 and July 26, 2026, both dates inclusive (the “Class Period”).

Details of the securities class action complaint can be accessed by clicking Capricor Therapeutics Class Action.

Capricor Shareholder Derivative Complaint Filed

On August 7, 2026, a verified shareholder derivative complaint was filed in federal court alleging that during the Relevant Period (December 17, 2025-July 26, 2026), the individual Capricor’s Defendants breached their fiduciary duties by personally making and/or causing the Company to make to the investing public a series of materially false and misleading statements regarding the Company’s business, operations, and prospects.

According to the complaint, the individual Defendants willfully or recklessly made and/or caused the Company to make false and misleading statements that failed to disclose, among other things, that:

(1) the pre-specified statistical analysis plan used for analysis of clinical data for Deramiocel was altered;

(2) the FDA did not agree to those alterations prior to the Company’s resubmission of the Deramiocel Biologics License Application, and as a result, there was a substantial risk of the FDA disapproving of the clinical results for lack of substantial evidence of effectiveness of Deramiocel; and, consequently,

3) the regulatory approval of Deramiocel for the treatment of Duchenne muscular dystrophy was at substantial risk.

A copy of the shareholder derivative complaint can be viewed by clicking “Capricor Shareholder Derivative Complaint.” 

Capricor Investors May Have Legal Claims

Capricor investors who acquired their securities during the Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating whether the proposed acquisition of Utz Brands, Inc. (“Utz” or the “Company”) (NYSE: UTZ) by Germany-based Intersnack Group GmbH & Co. KG (“Intersnack Group”) is fair to Utz and its shareholders.

On July 21, 2026, Utz announced that the companies have entered into a definitive agreement whereby Intersnack Group will acquire all outstanding shares of Class A Utz Common Stock for $14.25 per share in cash. After the acquisition, Utz will become a private company with the Rice and Lissette Family Entities and Intersnack Group each owning 50% of Utz.

Kehoe Law Firm is investigating whether the consideration offered to Utz shareholders adequately values the Company and whether Utz’s board of directors fulfilled its fiduciary duties in connection with the proposed transaction.

Utz Brands Investors Encouraged to Contact Kehoe Law Firm, P.C. 

Utz Brands investors are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating whether the proposed acquisition of Distribution Solutions Group, Inc. (“Distribution Solutions” or the “Company”) (NASDAQ: DSGR) by affiliates of LKCM Headwater Investments, LLC (“LKCM Headwater”) is fair to the Company’s shareholders.

On July 16, 2026, Distribution Solutions announced that it had entered into a definitive merger agreement under which newly formed entities controlled by LKCM Headwater would acquire all outstanding shares of Distribution Solutions common stock not already owned by LKCM Headwater and its affiliates for $35.00 per share in cash.

LKCM Headwater and its affiliates currently own approximately 79% of Distribution Solutions’ outstanding common stock. Additionally, Distribution Solutions Chairman and CEO, J. Bryan King, serves as Managing Partner of LKCM Headwater.

Upon completion of the proposed transaction, Distribution Solutions will become a privately held, wholly-owned subsidiary of LKCM Headwater and its affiliates, and the Company’s common stock will no longer be listed on Nasdaq.

Kehoe Law Firm is investigating whether the consideration offered to Distribution Solutions shareholders adequately values the Company and whether the Company’s board of directors fulfilled its fiduciary duties in connection with the proposed transaction.

DSGR Investors Encouraged to Contact Kehoe Law Firm, P.C. 

Distribution Solutions investors are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Immix Biopharma Stock Drops Following Report Concerning Chief Medical Officer 

Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. (“Immix Biopharma”) (NASDAQ: IMMX).

On July 20, 2026, Investing.com reported that “Immix Biopharma Inc . . . shares fell 13% . . . after STAT News reported that one of Rhode Island’s most-wanted fugitives appears to have been working as an executive at the company.”

Additionally, “[a]ccording to the report, Ronald Fischer, 70, was arrested last week by federal and Rhode Island authorities after they tracked and boarded a 56-foot sailboat off the coast of New Jersey. Fischer, a former anesthesiologist, disappeared in 2005 while on trial for first-degree sexual assault.”

On this news, shares of Immix Biopharma dropped more than 13% during intraday trading on July 20, 2026.

IMMX Investors With Financial Losses Encouraged to Contact Kehoe Law Firm, P.C. 

Immix Biopharma investors with financial losses are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning clients are not responsible for any fees or litigation expenses.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]

Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors who purchased or otherwise acquired Pentair plc (“Pentair” or the “Company”) (NYSE: PNR) securities between April 28, 2026 and July 14, 2026, both dates inclusive, as well as investors who purchased Pentair ordinary shares during the expanded period of March 11, 2025 through July 14, 2026, both dates inclusive.

Pentair Announces Preliminary Financial Results, Reduces Full-Year Financial Guidance & Reports CFO’s Departure

On July 14, 2026, Pentair announced preliminary financial results for the second quarter of 2026, substantially reduced its full-year financial guidance, and announced the departure of its Chief Financial Officer.

Pentair disclosed that it expected second-quarter sales of approximately $930 million, representing a decline of approximately 17%, compared with the Company’s prior expectation of approximately 1% sales growth. Pentair also disclosed that second-quarter adjusted earnings per share were expected to be approximately $1.12, substantially below the Company’s previous guidance of between $1.47 and $1.50 per share.

Pentair further reduced its full-year 2026 guidance, expecting annual sales to decline approximately 4% to 7% compared with its prior forecast for sales growth of approximately 2% to 4%. Pentair also reduced its expected adjusted earnings per share to between $4.60 and $4.80, compared with its previous guidance of between $5.30 and $5.40 per share.

Following these disclosures, the price of Pentair common stock declined sharply trading down more than 15% during intraday trading on July 15, 2026. 

Class Action Filed on Behalf of Pentair Investors

On August 3, 2026, a class action lawsuit alleging violations of federal securities laws was filed against Pentair on behalf of persons and entities that purchased or otherwise acquired Pentair securities between April 28, 2026 and July 14, 2026, inclusive (the “Class Period”).

According to the complaint, throughout the Class Period, the Pentair Defendants allegedly made materially false and/or misleading statements and failed to disclose material adverse facts concerning the Company’s business, operations, and prospects. Allegedly, the Pentair Defendants failed to disclose that significant inventory destocking in the Pool channel was adversely affecting the Company’s sales and operating income. As a result, the complaint alleges that Defendants’ positive statements about Pentair’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

A copy of the complaint filed on August 3, 2026 can be viewed by clicking “Pentair Securities Class Action Complaint.” 

New Class Action Expands the Pentair Class Period

On August 12, 2026, a securities class action lawsuit was filed against Pentair on behalf of investors who purchased Pentair ordinary shares between March 11, 2025 and July 14, 2026, both dates inclusive (“Expanded Class Period”).

According to the complaint, the Defendants allegedly made materially false and misleading statements concerning the implementation and performance of Pentair’s “80/20” sales program. The complaint alleges that the program impaired longstanding commercial relationships, caused widespread customer dissatisfaction, and led customers—particularly within Pentair’s Pool segment—to move business to competitors.

The complaint further alleges that the Defendants failed to disclose that certain Pool customers purchased inventory beyond their current needs ahead of anticipated price increases and received rebates above historical norms. These practices allegedly inflated short-term sales and revenue at the expense of future periods and exposed Pentair to undisclosed operational and financial risks.

On July 14, 2026, Pentair disclosed that customer destocking had reduced second-quarter Pool segment net sales by approximately $170 million. The complaint alleges that, as the relevant information was revealed, Pentair ordinary shares declined more than 40% from their Class Period high, causing investors substantial financial losses.

A copy of the complaint filed on August 12, 2026 can be viewed by clicking “Pentair Securities Class Action Complaint (Expanded Class Period).”

Pentair Investors May Have Legal Claims

Investors who acquired Pentair securities during either Class Period are encouraged to complete Kehoe Law Firm’s Stockholder Information Request Form or contact Michael Yarnoff, Esq., (215) 792-6676, Ext. 804, [email protected], [email protected], to learn more about the investigation and receive a free, no-obligation evaluation of potential legal claims.  

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action firm dedicated to protecting investors and consumers from fraud and misconduct. Our attorneys have served as Lead or Co-Lead Counsel in major securities cases, recovering over $10 billion for institutional and individual investors.

Our firm litigates securities fraud, fiduciary breaches, unfair mergers and acquisitions, and antitrust violations, while also representing whistleblowers and advocating for victims of data breaches, consumer fraud, vehicle and product defects, employment law violations, retirement plan mismanagement, and other corporate and business misconduct. With a results-driven approach, we pursue justice and substantial recoveries for those we represent.

There is no cost or obligation to speak with the firm, and there are no upfront fees or litigation costs. We handle class action matters on a contingency-fee basis. Any attorneys’ fees or expenses sought in connection with a recovery are subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]